Changes in the Intestinal Microbiome due to Faecal Bacteriotherapy in Patients with Chronic Active Ulcerative Colitis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00003824

Enrollment

Registered

2012-05-07

Start date

2011-07-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

fecal bacteriotherapy K51

Interventions

Group 1: At enrolment (day 1) the patient will undergo a rectosigmoidoscopy without any prior bowel lavage or enema. Tissue samples will be collected from the rectum as well as from the sigma for hist

Eligibility

Sex/Gender

All

Age

17 Years to 80 Years

Inclusion criteria

Inclusion criteria: Patient: chronic active UC with indication to total colectomy, age >18 and <80, informed consent. Donor: infomed consent

Exclusion criteria

Exclusion criteria: Patient: oral anticoagulation, coagulopathy, pregnancy. Donor: any severe disease (infection, malignancy, autoimmune idsease), any kind of diarrhoea, GI infections or any intestinal disease, antibiotic therapy within the last 6 month.

Design outcomes

Primary

Measure	Time frame
The primary endpoint is a sustained reduction of at least 2 points in the MAYO score. Time points of clinical visitation performed by the principal investigator incl. MAYO score, blood tests and endoscopy are day 3,10, 30 and 90.	—

Secondary

Measure	Time frame
Secondary endpoint is a sustained chance of intestinal microbiota in patients with chronic activity of UC due to fecal bacteriotherapy.	—

Countries

Austria

Contacts

Public ContactPatrizia Kump

Klinische Abteilung für Gastroenterologie und Hepatologie Medizinische Universität Graz

patrizia.kump@medunigraz.at+43 316 385 80270

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026